Search
Mink Therapeutics Inc
INKTAdd to Watchlist
12.140USD
-0.070-0.57%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
57.13MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
2
analysts
Buy
Current Rating
39.000
Target Price
+221.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Mink Therapeutics Inc
INKT
2
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Mink Therapeutics Inc's price target?
Analysts forecast that Mink Therapeutics Inc's price target is USD 39.00, with the highest forecast at USD 43.00 and the lowest forecast at USD 35.00.
How have Mink Therapeutics IncINKT's recent earnings per share performed?
The market expectation was USD -0.57, while Mink Therapeutics IncINKT's earnings per share (EPS) for the previous quarter was USD -0.56. EPS for the next quarter is expected at USD -0.60.
What is the analyst rating for Mink Therapeutics Inc?
Based on the ratings of Mink Therapeutics Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
